Argent Biopharma ( (AU:RGT) ) just unveiled an announcement.
Argent BioPharma has announced the dispatch of documents for its upcoming General Meeting of shareholders scheduled for April 11, 2025. This meeting is a significant event for stakeholders, as it provides an opportunity to discuss the company’s strategic direction and operational plans, potentially impacting its market positioning and future developments.
More about Argent Biopharma
Argent BioPharma Limited is a clinical-stage biopharmaceutical company specializing in neuroimmunology. The company focuses on developing advanced nano-medicines to address unmet medical needs in central nervous system disorders and immune-related conditions. Its pipeline includes lead candidates like CannEpil®, CogniCann®, and CimetrA®, targeting complex diseases lacking effective treatments.
YTD Price Performance: -50.86%
Average Trading Volume: 135,660
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $5.96M
For an in-depth examination of RGT stock, go to TipRanks’ Stock Analysis page.